JPRN-UMIN000013424已完成1 期
Safety evaluation of coadministration of erlotinib and theracurmin in non-small cell lung cancer patients - Safety evaluation of coadministration of erlotinib and theracurmin in non-small cell lung cancer patients
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional,observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)idiopathic pulmonary fibrosis, interstitial pneumonia, radiation pneumonitis, drug related pneumonitis 2)plueral, peritoneal, or pericardial effusion requiring drainage 3)active infection 4)unable to take oral medication 5)symptomatic eye disorders 6)pregnant or lactating 7)symptomatic brain metastasis 8)other malignancies 9)uncontrolled diabetes 10) active complications 11)patients whom physicians judged to be unsuitable for enrollment for other reasons
研究者
相似试验
招募中
不适用
Safety and feasibility of coadministration of erlotinib and Theracurmin (nanoparticle curcumin) in patients with advanced or recurrent non-small-cell lung canceradvanced or recurrent non-small-cell lung cancerJPRN-UMIN000006892School of Medicine, Keio University12
进行中（未招募）
不适用
Phase II trial of Erlotinib in combination with increasing dose of gemcitabine given as fixed dose rate infusion in advanced pancreatic cancer. - tarcevapancreasPatients with unresectable advanced or metastatic pancreatic cancerMedDRA version: 6.1Level: PTClassification code 10033609EUCTR2006-001238-41-ITAZIENDA OSPEDALIERA POLICLINICO DI MODENA
尚未招募
2 期
To evaluate the efficacy and safety of Erlotinib and Bevacizumab in patients with advanced Non-squamous Non-Small Cell Lung Cancer with brain metastasis who acquired resistance to prior EGFR-TKI treatment harboring EGFR mutation.on-Small-Cell Lung CancerJPRN-UMIN000012515Department of Respiratory Medicine, Kumamoto University Hospital16
已完成
不适用
Efficacy and pharmacokinetics study of erlotinib in patients with non-small cell lung cancerAdvanced non-small cell lung cancerJPRN-UMIN000012862Shizuoka cancer center70
已完成
2 期
A randomized phase II study of Erlotinib with or without Bevacizumab in NSCLC patients previouly treated with platinum-based chemotherapy containing bevacizumab. North Japan Lung Cancer Study Group Trial 1201JPRN-UMIN000007475orth Japan Lung Cancer Study Group64